The JAK1-Selective Inhibitor Filgotinib Displays an Anti-Inflammatory Biomarker Signature in Rheumatoid Arthritis Patients

The potent and selective JAK1 inhibitor filgotinib (GLPG0634, GS-6034) has been evaluated in a 24-week phase 2B study in combination with methotrexate (MTX) in active rheumatoid arthritis (RA) patients with inadequate response to MTX (DARWIN 1 study). The data gathered demonstrates a systemic anti-inflammatory activity of filgotinib in line with its clinical efficacy observed in RA patients.